Given that the ovarian cancer possesses SPON1-TRIM29 gene fusion, treatment with SPON1-TRIM29 inhibitors, such as siRNA or small molecules, would increase the efficacy of cancer drugs in patients. This evidence concerns the gene SPON1 and ovarian carcinoma.